Handelsinvest Investeringsforvaltning Lowers Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Handelsinvest Investeringsforvaltning cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,456 shares of the medical research company’s stock after selling 625 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.0% of Handelsinvest Investeringsforvaltning’s investment portfolio, making the stock its 17th biggest position. Handelsinvest Investeringsforvaltning’s holdings in Thermo Fisher Scientific were worth $2,009,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. WCM Investment Management LLC boosted its holdings in Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after acquiring an additional 2,928 shares during the period. Summa Corp. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $418,000. Phoenix Holdings Ltd. raised its position in Thermo Fisher Scientific by 21.4% in the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after purchasing an additional 1,654 shares in the last quarter. S. R. Schill & Associates raised its position in Thermo Fisher Scientific by 106.3% in the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after purchasing an additional 792 shares in the last quarter. Finally, Tsfg LLC raised its position in Thermo Fisher Scientific by 8.3% in the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 19 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,238,340.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,000 shares of company stock worth $12,532,780. 0.34% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TMO. Jefferies Financial Group reaffirmed a “buy” rating and issued a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Deutsche Bank Aktiengesellschaft lifted their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Barclays cut their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Robert W. Baird cut their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Finally, Citigroup began coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target on the stock. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $606.47.

Thermo Fisher Scientific Stock Down 0.7 %

Thermo Fisher Scientific stock opened at $530.35 on Wednesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a market cap of $202.45 billion, a PE ratio of 34.25, a price-to-earnings-growth ratio of 2.58 and a beta of 0.77. The stock’s 50 day moving average price is $574.71 and its 200 day moving average price is $563.50.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be given a dividend of $0.39 per share. The ex-dividend date is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s payout ratio is 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.